HYDROMORPHONE

First approved in 1972

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19NO3
Molecular Weight	285.3377
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2CCC4=O)=C35

InChI

InChIKey=WVLOADHCBXTIJK-YNHQPCIGSA-N

InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H19NO3
Molecular Weight	285.3377
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019034s029lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/11869661 | https://www.ncbi.nlm.nih.gov/pubmed/16433932

Hydromorphone (also known as dihydromorphinone and the brand name Dilaudid among others) is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. It also binds with kappa and delta receptors which are thought to mediate spinal analgesia, miosis and sedation.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16433932	Agonist 2752	279.0 nM [EC50]
Delta opioid receptor 81 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9301669	Partial Agonist 297
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18789923	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019034s029lbl.pdf	Palliative		Approved 8583	DILAUDID-HP Approved Use DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. DILAUDID-HP INJECTION is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer,around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering DILAUDID-HP Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
5.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
23.7 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
81% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340	unhealthy, 27 Health Status: unhealthy Age Group: 27 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15336340	Disc. AE: Sleepiness, Nausea... AEs leading to discontinuation/dose reduction: Sleepiness Nausea Sources: https://pubmed.ncbi.nlm.nih.gov/15336340
2 mg 3 times / day multiple, intravenous Recommended Dose: 2 mg, 3 times / day Route: intravenous Route: multiple Dose: 2 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	unhealthy, 40 Health Status: unhealthy Age Group: 40 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	Disc. AE: Respiratory arrest... AEs leading to discontinuation/dose reduction: Respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/21620461
4 mg 4 times / day multiple, oral Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	unhealthy, 67.7 Health Status: unhealthy Age Group: 67.7 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	Disc. AE: Somnolence, Aspiration pneumonia... AEs leading to discontinuation/dose reduction: Somnolence (serious, 1.14%) Aspiration pneumonia (grade 5, 1.14%) Toxic skin eruption (serious, 1.14%) Nausea and vomiting (serious, 1.14%) Sources: https://pubmed.ncbi.nlm.nih.gov/29659913
10 mg single, intravenous Overdose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	Disc. AE: Cardio-respiratory arrest... AEs leading to discontinuation/dose reduction: Cardio-respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/21620461
2 mg 6 times / day multiple, subcutaneous\|intramuscular Recommended Dose: 2 mg, 6 times / day Route: subcutaneous\|intramuscular Route: multiple Dose: 2 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf	Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf
4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	Disc. AE: Addiction, Abuse... AEs leading to discontinuation/dose reduction: Addiction Abuse Respiratory depression (grade 3-5) Withdrawal syndrome neonatal (grade 3-5) Coma (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf

AEs

AE	Significance	Dose	Population
Nausea	Disc. AE	540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340	unhealthy, 27 Health Status: unhealthy Age Group: 27 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15336340
Sleepiness	Disc. AE	540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340	unhealthy, 27 Health Status: unhealthy Age Group: 27 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15336340
Respiratory arrest	grade 5 Disc. AE	2 mg 3 times / day multiple, intravenous Recommended Dose: 2 mg, 3 times / day Route: intravenous Route: multiple Dose: 2 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	unhealthy, 40 Health Status: unhealthy Age Group: 40 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21620461
Aspiration pneumonia	grade 5, 1.14% Disc. AE	4 mg 4 times / day multiple, oral Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	unhealthy, 67.7 Health Status: unhealthy Age Group: 67.7 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29659913
Nausea and vomiting	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	unhealthy, 67.7 Health Status: unhealthy Age Group: 67.7 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29659913
Somnolence	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	unhealthy, 67.7 Health Status: unhealthy Age Group: 67.7 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29659913
Toxic skin eruption	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913	unhealthy, 67.7 Health Status: unhealthy Age Group: 67.7 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/29659913
Cardio-respiratory arrest	grade 5 Disc. AE	10 mg single, intravenous Overdose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21620461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/21620461
Respiratory depression	Disc. AE	2 mg 6 times / day multiple, subcutaneous\|intramuscular Recommended Dose: 2 mg, 6 times / day Route: subcutaneous\|intramuscular Route: multiple Dose: 2 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf
Abuse	Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf
Addiction	Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf
Respiratory depression	grade 3-5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf
Withdrawal syndrome neonatal	grade 3-5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf
Coma	grade 5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C8 1057	CYP3A5 446

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]

Drug as victim

Target	Modality	Activity
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5791	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5791
eMolecules	539218	https://www.emolecules.com/cgi-bin/more?vid=539218

PubMed

Title	Date	PubMed
Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model.	2003-11-14	14572875
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.	2003-11	12902992
[Combined use of intrathecal morphine and diclofenac suppository for postoperative analgesia after caesarean section].	2003-10	14598667
The use of long-acting opioids in chronic pain management.	2003-09	14567201
Oral vs. i.v. hydromorphone. Add a measure of caution.	2003-09	14562820
Comparison of morphine and hydromorphone analysis on reversed phase columns with different diameters.	2003-08-08	12899977
Calculating opioid dose conversions #36.	2003-08	14516504
Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002).	2003-08	12915905
Is the analgesic effect of systemic lidocaine mediated through opioid receptors?	2003-08	12859317
[Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].	2003-07-10	14587190
Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations.	2003-07	12850649
Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.	2003-07	12818953
Management of postoperative pain after T6 corpectomy: use of epidural bupivacaine and sufentanil--a case report.	2003-06	12847945
Oral oxycodone: new preparation. No better than oral morphine.	2003-06	12825566
Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats.	2003-05	12615487
Opioid equianalgesic conversion: the right dose.	2003-04-15	12690618
Morphine and hydromorphone for postoperative analgesia: focus on safety.	2003-04	12710006
Embolized crospovidone (poly[N-vinyl-2-pyrrolidone]) in the lungs of intravenous drug users.	2003-04	12692192
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.	2003-03-06	12618536
Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test.	2003-03	12745417
Changes in intraocular pressure and pupil size following intramuscular administration of hydromorphone hydrochloride and acepromazine in clinically normal dogs.	2003-03	12641847
Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.	2003-03	12570846
Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection.	2003-02-25	12535841
Postoperative hypoxemia and hypercarbia in healthy dogs undergoing routine ovariohysterectomy or castration and receiving butorphanol or hydromorphone for analgesia.	2003-02-01	12564595
A systematic review of hydromorphone in acute and chronic pain.	2003-02	12590032
Hydromorphone transfer into breast milk after intranasal administration.	2003-02	12587803
Activity of opioid ligands in cells expressing cloned mu opioid receptors.	2003-01-04	12513698
Catheter-associated masses in patients receiving intrathecal analgesic therapy.	2003-01	12505950
In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems.	2003	12901434
Envenomation by the Mexican beaded lizard: a case report.	2003	12807305
Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.	2003	12662124
Screening extemporaneously compounded intraspinal injections with the bacterial endotoxins test.	2002-12-15	12503341
Role of urine toxicology testing in the management of chronic opioid therapy.	2002-12-14	12479257
Clinical pharmacology of opioids for pain.	2002-12-14	12479250
Epidural and intrathecal analgesia for cancer pain.	2002-12	12516896
Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.	2002-11-18	12437765
Opioid rotation in the treatment of joint pain. A review of 67 cases.	2002-10	12477234
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.	2002-10	12423011
A field evaluation of five on-site drug-testing devices.	2002-10	12423006
Detection of cocaine analytes and opiates in nails from postmortem cases.	2002-10	12423005
Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.	2002-10	12357147
Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.	2002-09	12222557
A convenient synthesis of delta(7,8)-morphinan-6-one and its direct oxidation to 14-hydroxy-delta(7,8)-morphinan-6-one.	2002-08-05	12113823
The addition of hydromorphone to epidural fentanyl does not affect analgesia in early labour.	2002-06-18	12067873
The use of methadone for cancer pain.	2002-06	12170567
Pain management for joint arthroplasty: preemptive analgesia.	2002-06	12068423
Postthoracotomy pain management.	2002-05	12122825
New directions in pain management.	2002-02	12532190
Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report.	1992-05	1376887
Survey of pain management therapy provided for children with sickle cell disease.	1992-04	1373356

Patents

Sample Use Guides

In Vivo Use Guide

Subcutaneous or Intramuscular Administration: The usual starting dose of DILAUDID INJECTION is 1 mg to 2 mg every 2 to 3 hours as necessary. Depending on the clinical situation, the initial starting dose may be lowered in patients who are opioid naïve. Intravenous Administration: The initial starting dose is 0.2 to 1 mg every 2 to 3 hours. Intravenous administration should be given slowly, over at least 2 to 3 minutes, depending on the dose. The initial dose should be reduced in the elderly or debilitated and may be lowered to 0.2 mg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:52:43 GMT 2025` Edited by `admin` on `Wed Apr 02 09:52:43 GMT 2025`
Record UNII	Q812464R06
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROMORPHONE

Official Name

English

N02AA03

Preferred Name

English

HYDROMORPHON

Common Name

English

NOVOLAUDON

Common Name

English

JURNISTA

Common Name

English

hydromorphone [INN]

Common Name

English

IDS-NH-004

Code

English

HYDROMORPHONE [VANDF]

Common Name

English

MORPHINAN-6-ONE, 4,5-EPOXY-3-HYDROXY-17-METHYL-, (5.ALPHA.)-

Systematic Name

English

HYDROMORPHONE [MI]

Common Name

English

NSC-19046

Code

English

HYDROMORPHONE [HSDB]

Common Name

English

4,5.ALPHA.-EPOXY-3-HYDROXY-17-METHYLMORPHINAN-6-ONE

Systematic Name

English

Hydromorphone [WHO-DD]

Common Name

English

HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY K [EP IMPURITY]

Common Name

English

DIMORPHONE

Common Name

English

Classification Tree Code System Code

DEA NO.

9150